Everest Acquisition Everest Clinical Research Services acquired Brightech in December 2022. This strategic move may open opportunities for joint offerings, access to Everest's client network, and cross-selling Brightech’s end-to-end data solutions, including CDISC and CIMS, within the combined client base.

End-to-End Data Brightech provides end-to-end clinical data solutions—data management, biostatistics/SAS programming, medical writing, regulatory strategy, and regulatory submissions—along with specialty CDISC services and the proprietary Clinical Information Management Suite (CIMS). This positions the company for sponsors seeking a single partner for study design through submission.

Stable Client Base With 25+ long-term clients and a proven NDA approvals track record since 2002, Brightech demonstrates durable customer relationships and repeat business potential, suggesting opportunities to expand project scope within existing accounts.

Mid-market Focus As a small-to-mid-sized CRO with 11-50 employees and revenue between 25 and 50 million, Brightech targets mid-market pharma/biotech sponsors seeking specialized, high-touch data services, presenting a path for tiered service offerings, faster onboarding and scalable engagement models.

CDISC Alignment The emphasis on CDISC services and robust regulatory submissions aligns with growing pharma industry demand for standardized data management and efficient NDA/IND processes, signaling cross-sell potential into sponsors planning submissions and opportunities to expand into new therapeutic areas.